Post Hoc Analyses from ENVISION Study of GIVLAARI® (givosiran) Presented at HTRS Scientific Symposium

Post Hoc Analyses from ENVISION Study of GIVLAARI® (givosiran) Presented at HTRS Scientific Symposium

We presented post hoc analyses from the Phase 3 ENVISION study of givosiran in patients with acute hepatic porphyria (AHP) through Month 36 at the Hemostasis & Thrombosis Research Society (HTRS) Scientific Symposium, held on March 10-12 in Orlando, Florida.

Deering, et al. “Clinical Outcomes in Patients with Acute Hepatic Porphyria Treated with Givosiran Who Stopped Hemin Prophylaxis at Study Entry: Post hoc Analyses from the Phase 3 ENVISION Study Through Month 36”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.